-
Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
Sep 9, 2025, 16:22 PM -
Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States (US)
Sep 9, 2025, 16:22 PM -
Real-life-Persistence to Antifibrotic Treatments in the French Population
Sep 9, 2025, 16:22 PM -
Optimizing Workforce Efficiency and Reducing Waiting Lists Through Remote Monitoring in Obstructive Sleep Apnea (OSA) Care in NHS
Sep 9, 2025, 16:22 PM -
The Use of Real-World Evidence in Health Technology Assessment and the Application of the NICE RWE Framework: A Review of NICE Technology Appraisals
Sep 9, 2025, 16:22 PM -
Estimand Framework in the Setting of Observational Studies: Current Landscape and Future Directions
Sep 9, 2025, 16:22 PM -
From Anxiety to Hope: Understanding the Adoption of AI Counseling Tools for Anxiety Management
Sep 9, 2025, 16:22 PM -
Use of Data From Phase 3 RCTs in Earlier Lines of Therapy in Support of Noncomparative Evidence From Pivotal Phase 2 Studies
Sep 9, 2025, 16:22 PM -
Bridging the Uncertainty: Cancer Drugs Fund Entry and Exit Outcomes Over Three Years
Sep 9, 2025, 16:22 PM -
Scaling Responsible Healthcare Data Access With AI-Driven Sensitive Patient Variable Detection
Sep 9, 2025, 16:22 PM -
Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis
Sep 9, 2025, 16:22 PM -
Developing Best Practice for Generative AI in Health Economic Evaluation: Evidence From a Systematic Review and Stakeholder Engagement
Sep 9, 2025, 16:22 PM -
Care Now, Pay Later (CNPL): Evaluating the Budgetary and Access Implications of a Novel Financing Model for Inclisiran in Atherosclerotic Cardiovascular Disease (ASCVD) Patients in India
Sep 9, 2025, 16:22 PM -
Assessing Stakeholders’ Perceptions of the EU Health Technology Assessment Regulation and Access to Innovative Medicines in Europe and the Netherlands: Challenges, Opportunities, and Recommendations
Sep 9, 2025, 16:22 PM -
Artificial Intelligence-Based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA)
Sep 9, 2025, 16:22 PM -
Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data
Sep 9, 2025, 16:22 PM -
Evaluating the Performance of an Artificial Intelligence A-Powered Tool for Assessing Quality of Published Economic Evaluations: A Comparison With Human Reviewers Using the Drummond Checklist
Sep 9, 2025, 16:22 PM -
Multistakeholder Survey on Communication of Uncertainties in Cost-Effectiveness Analysis by the Institute of Clinical and Economic Review
Sep 9, 2025, 16:22 PM -
Assessing Known Groups and Convergent Validity of the EQ-5D-5L in Assessing the Health-Related Quality of Life of Individuals With Obesity Who Have and Have Not Received Bariatric Surgery
Sep 9, 2025, 16:22 PM -
Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024
Sep 9, 2025, 16:22 PM
